Patents by Inventor Christoph Arkona

Christoph Arkona has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer
    Patent number: 10683286
    Abstract: A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for treatment of acute myeloid leukemia.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 16, 2020
    Assignee: FREIE UNIVERSITAET BERLIN
    Inventors: Joerg Rademann, Ee Lin Wong, Christoph Arkona, Boo Geun Kim, Eric Nawrotzky
  • NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER
    Publication number: 20190382392
    Abstract: A furazan-3-carboxylic acid derivative or pharmaceutically acceptable salt thereof for treatment of acute myeloid leukemia.
    Type: Application
    Filed: October 5, 2017
    Publication date: December 19, 2019
    Inventors: Joerg Rademann, Ee Lin Wong, Christoph Arkona, Boo Geun Kim, Eric Nawrotzky
  • Method for cleaving the human growth hormone gh
    Publication number: 20040259192
    Abstract: The invention relates to a method for cleaving human growth hormone GH by means of matrix metalloproteinase MMP. It has been found that MMP-3 cleaves the growth hormone into two fragments, the 16 kDa fragment of which is stable. The invention solves the problem of providing means which positively influence both tumor growth, proliferative diabetic retinopathy and others as well as angiogenesis, in particular on treatment the cardiac infarction, retarded wound healing, menstrual cycle disturbances and others, by means of regulation of the human growth hormone.
    Type: Application
    Filed: January 12, 2004
    Publication date: December 23, 2004
    Inventors: Konrad Hermann, Christoph Arkona
  • 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
    Publication number: 20040044013
    Abstract: It is the object of this invention to discover and study new chemical substances of non-proteinogenic structure which have a matrix metalloproteinase (MMP)-inhibitory effect.
    Type: Application
    Filed: October 22, 2003
    Publication date: March 4, 2004
    Inventors: Jochen Heinicke, Uwe Klausmeier, Christoph Arkona, Siegfried Leistner
  • Tricylic mercaptomethyl-substituted 2,3-dihydro-quinazolin-5-ones and 2,3-dihydro-benzo-[1,2,4]-thiadiazin-5,5-dioxides as matrix metalloproteinase (MMP) inhibitors
    Publication number: 20040023953
    Abstract: The invention relates to mercaptomethyl-substituted thiazolo[2,3-b]quinazolines, oxazolo[2,3-b]quinazolines and imidazolo[2,1-b]quinazolines.
    Type: Application
    Filed: July 30, 2003
    Publication date: February 5, 2004
    Inventors: Uwe Kausmeier, Jochen Heinicke, Christoph Arkona